OpGen to Provide Business Update and Financial Results for the Third Quarter 2020
October 29 2020 - 6:30AM
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced
today that the Company will provide a business update and report
its third quarter 2020 financial results after the close of the
U.S. financial markets on Wednesday, November 11, 2020. OpGen’s
management team will host a live conference call and audio webcast
at 4:30 p.m. Eastern Time to discuss the Company’s financial
results and provide an update on business activities.
Conference Call Details |
|
U.S. Dial-in
Number: |
+1 (877) 705
6003 |
|
International Dial-in Number: |
+1 (201) 493 6725 |
|
Webcast: |
http://public.viavid.com/index.php?id=142176 |
|
Conference ID: |
13712431 |
|
|
|
Replay
Details |
|
U.S. Dial-in Number: |
+1 (844) 512 2921 |
|
International Dial-in Number: |
+1 (412) 317 6671 |
|
Replay PIN: |
13712431 |
Following the conclusion of the conference call, a replay will
be available through November 25, 2020. The live, listen-only
webcast of the conference call may also be accessed by visiting the
Investors section of the Company’s website at www.opgen.com. A
replay of the webcast will be available following the conclusion of
the call and will be archived on the Company’s website for 90
days.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew Bretzius FischTank
Marketing and PRmatt@fischtankpr.com
OpGen Investor Contact:Megan Paul Edison Group
mpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024